Optimal management of people with type 2 diabetes has increased in complexity over the last several years. The focus is not only on the management of hyperglycemia, but also on interventions that have been associated with a reduction in the development and progression of complications such as cardiovascular disease and chronic kidney disease. This program is focused on providing clinicians with a quick update on the optimal management of individuals with type 2 diabetes with chronic kidney disease or at high-risk of cardiovascular disease. This case-based practical program will provide healthcare professionals with a quick update on these topics to allow them to apply evidence-informed care in practice.
Beyond Glycemic Management: Optimizing Cardiovascular and Renal Outcomes in People with Type 2 Diabetes
CAN-eng
$0
free
Mainpro+
30 min
Diabetes, Medication Management
0.5 Credits
Course Description
Course Details
Expiry Date: 2025-10-01
Professions: Physician
Faculty
- Ronald Goldenberg, MD, FRCPC, FACE
- Robert Hauptman, BMSc, MD, MCFP
- Sofia Nastis, BMSc, MD, CCFP
- Jahan Lakhani, MD, CCFP
- Bilal Hatoum, BSc Pharm, RPh, APA, CDE
- Susie Jin, RPh, CDE, CRE
Accreditation
This activity meets the certification criteria of the College of Family Physicians of Canada and the Quebec College of Family Physicians, a continuing professional development accrediting organization recognized by the Collège des médecins du Québec and has been approved for up to 0.5 Mainpro+® Certified Activity credit(s).
CERT+ Session ID : 203427-001
Learning Objective(s)
Upon successful completion of this continuing education activity, you will be better able to:
- Analyze the components of the ABCDESSS approach in managing individuals with type 2 diabetes at high risk for cardiovascular disease
- Create treatment plans for adults with type 2 diabetes and chronic kidney disease or cardiovascular risk factors, integrating pharmacological interventions, lifestyle modifications, and regular monitoring strategies
- Evaluate the appropriateness of using SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists in adults with type 2 diabetes and chronic kidney disease, based on current evidence and guideline recommendations
- Apply evidence-based strategies to adjust antihyperglycemic agents and manage potential side effects in people with type 2 diabetes and varying levels of renal function